Display options
Share it on

Oncol Ther. 2016;4(2):199-210. doi: 10.1007/s40487-016-0026-y. Epub 2016 Aug 18.

Cutaneous CD8+ Cytotoxic T-Cell Lymphoma Infiltrates: Clinicopathological Correlation and Outcome of 35 Cases.

Oncology and therapy

Marion Wobser, Theresa Reinartz, Sabine Roth, Matthias Goebeler, Andreas Rosenwald, Eva Geissinger

Affiliations

  1. Department of Dermatology, University Hospital Würzburg, Würzburg, Germany.
  2. Institute of Pathology and Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany.

PMID: 28261650 PMCID: PMC5315091 DOI: 10.1007/s40487-016-0026-y

Abstract

INTRODUCTION: Cytotoxic CD8+ T-cell lymphomas are only rarely encountered and thus remain only poorly characterized. Our aim was to collect and correlate clinical and histological data of CD8+ skin lymphoma infiltrates to obtain a proper subtype assignment of CD8+ skin lymphoma infiltrates and to derive putative prognostic markers thereof.

METHODS: Formalin-fixed and paraffin-embedded (FFPE) tissue of 35 patients with CD8+ cytotoxic cutaneous T-cell lymphoma infiltrates was retrieved from the archives of the Institute of Pathology and the Department of Dermatology, University Hospital Wuerzburg, dating back from 1998 until 2015. Cytological, histological, immunohistochemical and molecular genetic features were assessed and correlated with respective clinical data.

RESULTS: The identified cases of CD8+ cytotoxic atypical lymphoproliferative infiltrates of the skin (

CONCLUSION: Cutaneous infiltrates of CD8+ cytotoxic T-cell lymphoma comprise clinically and histologically heterogeneous entities of either primary cutaneous T-cell lymphomas or secondary infiltrates of otherwise systemic peripheral T-cell lymphomas. A thorough clinicopathological correlation with respective staging examinations remains the mainstay for correct subtype assignment and proper prognostication as long as no better markers have been defined.

Keywords: Cutaneous lymphomas; Cytotoxic; Histology; Prognosis

References

  1. Am J Surg Pathol. 2007 Dec;31(12):1887-92 - PubMed
  2. J Cutan Pathol. 2015 Jun;42(6):427-34 - PubMed
  3. Am J Surg Pathol. 2013 Mar;37(3):375-84 - PubMed
  4. Semin Hematol. 2014 Jan;51(1):5-16 - PubMed
  5. Blood. 2016 May 19;127(20):2375-90 - PubMed
  6. Blood. 2005 May 15;105(10):3768-85 - PubMed
  7. J Am Acad Dermatol. 2010 Feb;62(2):300-7 - PubMed
  8. Clin Cancer Res. 2004 Aug 1;10(15):4971-82 - PubMed
  9. Br J Dermatol. 2015 Jun;172(6):1573-80 - PubMed
  10. Virchows Arch. 2004 Oct;445(4):334-43 - PubMed
  11. Blood. 2012 Aug 16;120(7):1466-9 - PubMed
  12. Med Sci (Paris). 2015 Oct;31(10):841-52 - PubMed
  13. Br J Haematol. 2010 Jul;150(1):21-7 - PubMed
  14. J Clin Oncol. 2008 Sep 1;26(25):4124-30 - PubMed
  15. Blood. 2003 May 1;101(9):3407-12 - PubMed
  16. J Cutan Pathol. 2002 Sep;29(8):465-72 - PubMed
  17. Hematol Oncol. 2013 Jun;31 Suppl 1:51-6 - PubMed
  18. J Am Acad Dermatol. 1990 Apr;22(4):569-77 - PubMed
  19. Blood. 2003 Sep 15;102(6):2213-9 - PubMed
  20. Leuk Lymphoma. 2009 Oct;50(10):1647-60 - PubMed
  21. Am J Dermatopathol. 2009 Jun;31(4):317-22 - PubMed
  22. Blood. 2014 May 8;123(19):2915-23 - PubMed
  23. Blood. 2011 Mar 24;117(12):3402-8 - PubMed
  24. Blood Rev. 2016 Mar;30(2):89-100 - PubMed
  25. J Clin Invest. 2007 Mar;117(3):823-34 - PubMed
  26. Histopathology. 2015 Oct;67(4):425-41 - PubMed
  27. J Clin Oncol. 2015 Nov 10;33(32):3766-73 - PubMed
  28. Am J Pathol. 1999 Aug;155(2):483-92 - PubMed
  29. J Clin Oncol. 2006 Jun 1;24(16):2472-9 - PubMed

Publication Types